Catalent Inc logo

Catalent Inc (CTLT)

Market Open
20 Jun, 20:00
NYSE NYSE
$
63. 48
0
0%
$
11.09B Market Cap
- P/E Ratio
0% Div Yield
13,629,167 Volume
1.01 Eps
$ 63.48
Previous Close
Day Range
63.44 63.5
Year Range
41.15 63.5

Summary

CTLT trading today higher at $63.48, an increase of 0% from yesterday's close, completing a monthly increase of 4.17% or $2.54. Over the past 12 months, CTLT stock gained 42.68%.
CTLT is not paying dividends to its shareholders.
The last earnings report, released on Feb 07, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0%, based on the last three reports.
The stock of the company had never split.
The company's stock is traded on 0 different exchanges and in various currencies, with the primary listing on NYSE (USD).
Want to track CTLT and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

CTLT Chart

Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus

Novo Holdings looks to double Catalent size with eye on Trump US manufacturing focus

Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired contract drugmaker Catalent over five years, a senior partner at the investment firm said, as it prepares for a likely focus on U.S. manufacturing by President-elect Donald Trump.

Reuters | 5 months ago
Novo Holdings completes $16.5 bln takeover of Catalent

Novo Holdings completes $16.5 bln takeover of Catalent

Novo Holdings has completed its $16.5 billion takeover of Catalent , the contract drug manufacturer announced on Wednesday, days after the companies said all regulatory closing conditions were fulfilled.

Reuters | 6 months ago
Regulatory conditions on Novo Holdings' $16.5 bln Catalent deal fulfilled, companies say

Regulatory conditions on Novo Holdings' $16.5 bln Catalent deal fulfilled, companies say

All regulatory closing conditions related to Novo Holdings' $16.5 billion acquisition of U.S. contract drug maker Catalent had been fulfilled, the companies said on Saturday, adding that the transaction is expected to be completed in the coming days.

Reuters | 6 months ago

Catalent Inc (CTLT) FAQ

What is the stock price today?

The current price is $63.48.

On which exchange is it traded?

Catalent Inc is listed on NYSE.

What is its stock symbol?

The ticker symbol is CTLT.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, the market cap is 11.09B.

Has Catalent Inc ever had a stock split?

No, there has never been a stock split.

Catalent Inc Profile

Drug Manufacturers - Specialty & Generic Industry
Healthcare Sector
Mr. Alessandro Maselli CEO
NYSE Exchange
US1488061029 ISIN
United States Country
17,000 Employees
- Last Dividend
- Last Split
31 Jul 2014 IPO Date

Overview

Catalent, Inc. is a global leader in delivering innovative solutions for drug development, biologic therapeutics, and consumer health products. With its foundation dating back to 1933, Catalent prides itself on its comprehensive expertise in advancing molecules, biologics, and consumer health products from early development to full-scale production. The company operates through two main segments: Biologics, and Pharma and Consumer Health, providing a broad spectrum of services worldwide. Catalent is committed to serving the pharmaceutical, biotechnology, consumer health, animal health, medical devices, and cosmetics industries. Headquartered in Somerset, New Jersey, Catalent stands as a pivotal partner for companies in various healthcare sectors, facilitating the pathway from laboratory to market.

Products and Services

Biologics Segment Services:

  • Biologic Protein, Cell, and Gene Therapy Development: Offers formulation, development, and manufacturing services for a broad range of therapeutics including biologic proteins, cell gene therapies, pDNA, iPSCs, oncolytic viruses, and vaccines.
  • Parenteral Dose Forms Manufacturing: Specializes in formulation, development, and manufacturing for parenteral dose forms such as vials, prefilled syringes, and cartridges.
  • Large Molecule Analytical Development and Testing: Provides analytical development and testing services, focusing on large molecules.

Pharma and Consumer Health Segment Services:

  • Soft Capsule Development and Manufacturing: Offers formulation, development, and manufacturing services for soft capsules utilized in prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
  • Diverse Dose Forms Development and Manufacturing: Provides services for the development and manufacturing of oral, nasal, inhaled, and topical dose forms.
  • Clinical Supply Services: Offers manufacturing, packaging, storage, distribution, and inventory management for clinical trials, covering small-molecule drugs, protein-based biologics, and cell and gene therapies.
  • Pre-Clinical and Commercial Scale Manufacturing: Supplies pre-clinical screening, formulation, analytical development, and cGMP manufacturing services for a variety of formats including softgel capsules, Zydis fast-dissolve tablets, oral solid-dose formats, dry powder inhalers, and nasal delivery devices.

Additional Services and Solutions:

  • Direct-to-Patient and Demand-Led Clinical Supply Solutions: Catalent offers FlexDirect and FastChain services for innovative and flexible clinical supply and distribution.
  • Fill and Finish Operations for Injectables: Provides specialized fill and finish operations for injectable products, ensuring quality and efficiency in the final stages of pharmaceutical manufacturing.
  • Integrated Development and Supply Chain Solutions: Offers comprehensive solutions that streamline the product development lifecycle, from development through to supply chain optimization.

Contact Information

Address: 14 Schoolhouse Road
Phone: 732 537 6200